CC
NTLA icon

Corton Capital’s Intellia Therapeutics NTLA Stock Holding History

Corton Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,137
Closed -$255K – 341
2025
Q2 		$255K Buy
27,137
+14,172
+109% +$116K 0.3% 127
2025
Q1 		$92.2K Buy
+12,965
New +$131K 0.3% 136
2024
Q3 		– Sell
-19,535
Closed -$437K – 606
2024
Q2 		$437K Buy
19,535
+10,813
+124% +$257K 0.23% 73
2024
Q1 		$240K Sell
8,722
-1,464
-14% -$40.7K 0.09% 352
2023
Q4 		$311K Sell
10,186
-3,902
-28% -$112K 0.1% 308
2023
Q3 		$445K Buy
14,088
+6,740
+92% +$261K 0.22% 118
2023
Q2 		$300K Buy
7,348
+741
+11% +$30K 0.14% 214
2023
Q1 		$246K Buy
+6,607
New +$259K 0.17% 185

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's NTLA Position: Q3 2025 in Review

Corton Capital sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 27,137 shares — an estimated $255K sold.

Corton Capital first reported a position in NTLA in Q1 2023 and held it in 8 quarters. The position peaked at $445K in Q3 2023. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Corton Capital reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Corton Capital sold 27,137 Intellia Therapeutics shares in Q3 2025, an estimated $255K.
  • Corton Capital first reported a position in Intellia Therapeutics in Q1 2023 and held it in 8 quarters.
  • Corton Capital's Intellia Therapeutics position peaked at $445K in Q3 2023.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.